Boston Scientific announced an agreement to acquire Penumbra for about $14.5 billion, a transaction aimed at expanding Boston Scientific’s presence in thrombectomy and embolization markets. Penumbra makes clot-removal devices for stroke and pulmonary embolism and reported strong revenue growth; the deal, payable in cash and stock, requires shareholder approval and is expected to close in 2026. Separately, the FDA cleared Boston Scientific’s new pulsed-field ablation catheter Farapoint for use as an adjunctive device in persistent atrial fibrillation needing cavotricuspid isthmus ablation. The approval complements Boston Scientific’s Farapulse family and gives the company a new focal tool alongside single-shot devices. Combining an acquisition that buys growth in thrombectomy with a regulatory win in electrophysiology strengthens Boston Scientific’s near-term commercial positioning across cardiovascular segments.